All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub
Brought to you by Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, Sobi, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Lilly and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
FDA grants RMAT and fast track designation to cema-cel for first-line consolidation in MRD-positive LBCL
FDA grants RMAT and fast track designation to cema-cel for first-line consolidation in MRD-positive LBCL
On July 29, 2026, the FDA granted regenerative medicine advanced therapy (RMAT) designation and fast track designation to cemacabtagene ansegedleucel (cema-cel) for first-line consolidation therapy in patients with MRD-positive LBCL who achieved a complete or partial response.
Jul 30, 2026|Large B-cell lymphoma
Phase III POLAR BEAR trial: Pola-R-mini-CHP vs R-mini-CHOP in elderly or frail patients with DLBCL
Phase III POLAR BEAR trial: Pola-R-mini-CHP vs R-mini-CHOP in elderly or frail patients with DLBCL
Results from the phase III POLAR BEAR trial, evaluating polatuzumab vedotin + rituximab + cyclophosphamide + dox...
Jul 30, 2026|EHA 2026
Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs
Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs
During the Lymphoma Hub virtual symposium, Susan O’Brien, University of California Irvine, US, discussed the mechanism of a...
Jul 29, 2026|CLL
CLL14: Venetoclax-obinutuzumab in previously untreated CLL
CLL14: Venetoclax-obinutuzumab in previously untreated CLL
During the EHA 2026 Congress, Kirsten Fischer presented final analysis results from the CLL14 study, evaluating fixed-duration venetoclax + obinutuzumab...
Jul 27, 2026|EHA 2026
Carousel item
Carousel item
Carousel item
Gilles Salles
Gilles Salles

"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology"

Your opinion matters

In patients with R/R LBCL who progress after CAR‑T, which of the following data would most strengthen your confidence in considering BV+R2?

Recent content

VIEW ALL
Phase III EPCORE DLBCL-1 trial: Epcoritamab vs CIT in R/R LBCL
Phase III EPCORE DLBCL-1 trial: Epcoritamab vs CIT in R/R LBCL
During the EHA2026 Congress, Christopher Fox presented primary results from the phase III randomized EPCORE DLBCL-1 trial (NCT04628494), evaluating ...
Jul 23, 2026|EHA 2026
Phase III SOUNDTRACK-F1 trial: Surovatamig + rituximab in previously untreated FL
Phase III SOUNDTRACK-F1 trial: Surovatamig + rituximab in previously untreated FL
Results from the phase III SOUNDTRACK-F1 trial, evaluating surovatamig + rituximab vs chemotherapy + rituximab in patients with p...
Jul 21, 2026|EHA 2026
Phase I/Ib BGB-11417-101 trial: Sonrotoclax + zanubrutinib in TN CLL/SLL
Phase I/Ib BGB-11417-101 trial: Sonrotoclax + zanubrutinib in TN CLL/SLL
Results from the phase I/Ib BGB-11417-101 study evaluating sonrotoclax + zanubrutinib in patients with treatment-naïve (TN) CLL/SLL were p...
Jul 17, 2026|CLL
EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?
EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?
Following the EHA2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Mem...
Jul 15, 2026|EHA 2026

Most read

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial
Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial
During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss the results f...
Jun 25, 2026|CLL
EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?
EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?
During the EHA 2026 Congress, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We ...
Jun 17, 2026|EHA 2026
Visual Abstract | The role of NGS in detecting resistance to targeted therapies in CLL
Visual Abstract | The role of NGS in detecting resistance to targeted therapies in CLL
NGS identifies resistance mutations in CLL receiving targeted therapy, highlighting clonal complexity and informing future t...
Jun 26, 2026|CLL
EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?
EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?
Following the EHA2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Mem...
Jul 15, 2026|EHA 2026

Lymphoma Hub symposiums

VIEW ALL
Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs
Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs
During the Lymphoma Hub virtual symposium, Susan O’Brien, University of California Irvine, US, discussed the mechanism of a...
Jul 29, 2026|CLL
Symposium Series | Customizing therapy for MCL
Symposium Series | Customizing therapy for MCL
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Cust...
Sep 12, 2025|ICML 2025
Symposium | Customizing therapy for MCL: Q&A
Symposium | Customizing therapy for MCL: Q&A
The Lymphoma Hub symposium titled ‘Customizing therapy for mantle cell lymphoma’, hosted at the 18th International Conference on Malignant Lymphoma, concluded with a ...
Aug 19, 2025|ICML 2025
Symposium | Current therapies for MCL and their combinations
Symposium | Current therapies for MCL and their combinations
Michael Wang, MD Anderson Cancer Center, Houston, US, presented the third session at the recent Lymphoma Hub symposium, titled ‘Customizing therapy fo...
Aug 8, 2025|ICML 2025

Steering Committee meetings

VIEW ALL
Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial
Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial
During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss the results f...
Jun 25, 2026|CLL
Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial
Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial
During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the p...
Nov 20, 2025|DLBCL
Anti-CD19 monoclonal antibodies for the treatment of DLBCL
Anti-CD19 monoclonal antibodies for the treatment of DLBCL
During the Lymphoma Hub Steering Committee meeting, Grzegorz Nowakowski, the Mayo Clinic, Rochester, US, chaired a discussion on anti-CD19 monoclonal an...
Jul 1, 2025|DLBCL
CELMoDs for the treatment of non-Hodgkin lymphoma
CELMoDs for the treatment of non-Hodgkin lymphoma
During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on CELMoDs for the ...
Jun 27, 2025

Drug updates

VIEW ALL
Important announcement
🚨NEWS🚨 @US_FDA grants RMAT and fast track designation to cemacabtagene ansegedleucel, an allogeneic CAR T-cell therapy, for first-line consolidation in patients with MRD-positive LBCL. Read more: https://bit.ly/3TsPXrK
Jul 30, 2026
Important announcement
Korea’s MFDS approves expanded indication for epcoritamab in combination with lenalidomide + rituximab for the treatment of adults aged ≥18 years with R/R FL, based on results from the EPCORE FL-1 trial. Read more: https://bit.ly/4yBsLYi
Jul 28, 2026
Important announcement
🚨NEWS🚨 @EU_Commission approves epcoritamab in combination with lenalidomide + rituximab for the treatment of adults with R/R FL, based on results from the EPCORE FL-1 trial. Read more: https://bit.ly/44glak8
Jul 7, 2026
Important announcement
🚨NEWS🚨 @EMA_News CHMP issued a positive opinion recommending the approval of pirtobrutinib for adult patients with CLL across all lines of therapy, regardless of BTKi exposure, based on results from the BRUIN CLL-313 and -314 trials. Read more: https://bit.ly/3SO7iuL
Jun 29, 2026